INTRODUCTION: The goals of scale-up of antiretroviral therapy (ART) have expanded from prevention of morbidity and death to include prevention of transmission. Morbidity and mortality risk are associated with CD4 count; transmission risk depends on plasma viral load (VL). This study aimed to describe CD4 count and VL distributions among HIV-infected individuals in a South African township to gain insights into the potential impact of ART scale-up on community HIV transmission risk. METHODS: A random sample of 10% of the adult population was invited to attend an HIV testing service. Study procedures included a questionnaire, HIV testing, CD4 count, and VL testing. RESULTS: One thousand one hundred forty-four (88.0%) of 1300 randomly selected individuals participated in the study. Two hundred sixty tested positive, giving an HIV prevalence of 22.7% [95% confidence interval (CI): 20.3 to 25.3]. A third of all HIV-infected individuals (33.5%, 95% CI: 27.8 to 39.6) reported taking ART. The median CD4 count was 417 cells per microliter (interquartile range, 285-627); 33 (12.7%, 95% CI: 8.9 to 17.4) had a CD4 count of ≤200 cells per microliter. VL measurements were available for 219 individuals (84.2%) and were undetectable in 72 (33.9%), >1500 copies per milliliter in 127 (58.0%) and >10,000 copies per milliliter in 96 (43.8%). Of those reporting they were receiving ART, 30.4% had a VL >1500 copies per milliliter compared with 58.0% of those reporting they were not receiving ART. CONCLUSIONS: A small proportion of those living with HIV in this community had a CD4 count of <200 cells per microliter; more than half had a VL high enough to be associated with considerable transmission risk. A substantial proportion of HIV-infected individuals remained at risk of transmitting HIV even after starting ART.
INTRODUCTION: The goals of scale-up of antiretroviral therapy (ART) have expanded from prevention of morbidity and death to include prevention of transmission. Morbidity and mortality risk are associated with CD4 count; transmission risk depends on plasma viral load (VL). This study aimed to describe CD4 count and VL distributions among HIV-infected individuals in a South African township to gain insights into the potential impact of ART scale-up on community HIV transmission risk. METHODS: A random sample of 10% of the adult population was invited to attend an HIV testing service. Study procedures included a questionnaire, HIV testing, CD4 count, and VL testing. RESULTS: One thousand one hundred forty-four (88.0%) of 1300 randomly selected individuals participated in the study. Two hundred sixty tested positive, giving an HIV prevalence of 22.7% [95% confidence interval (CI): 20.3 to 25.3]. A third of all HIV-infected individuals (33.5%, 95% CI: 27.8 to 39.6) reported taking ART. The median CD4 count was 417 cells per microliter (interquartile range, 285-627); 33 (12.7%, 95% CI: 8.9 to 17.4) had a CD4 count of ≤200 cells per microliter. VL measurements were available for 219 individuals (84.2%) and were undetectable in 72 (33.9%), >1500 copies per milliliter in 127 (58.0%) and >10,000 copies per milliliter in 96 (43.8%). Of those reporting they were receiving ART, 30.4% had a VL >1500 copies per milliliter compared with 58.0% of those reporting they were not receiving ART. CONCLUSIONS: A small proportion of those living with HIV in this community had a CD4 count of <200 cells per microliter; more than half had a VL high enough to be associated with considerable transmission risk. A substantial proportion of HIV-infected individuals remained at risk of transmitting HIV even after starting ART.
Authors: Amanda D Castel; Montina Befus; Sarah Willis; Angelique Griffin; Tiffany West; Shannon Hader; Alan E Greenberg Journal: AIDS Date: 2012-01-28 Impact factor: 4.177
Authors: Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Oliver Laeyendecker; Andrew D Redd; Tom Lutalo; Ronald H Gray; Maria Wawer; Victor Ssempijja; Jordyn Gamiel; John Baptist Bwanika; Fred Makumbi; Fred Nalugoda; Pius Opendi; Godfrey Kigozi; Anthony Ndyanabo; Boaz Iga; Noah Kiwanuka; Nelson Sewankambo; Steven J Reynolds; David Serwadda; Thomas C Quinn Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Pauli N Amornkul; Hilde Vandenhoudt; Peter Nasokho; Frank Odhiambo; Dufton Mwaengo; Allen Hightower; Anne Buvé; Ambrose Misore; John Vulule; Charles Vitek; Judith Glynn; Alan Greenberg; Laurence Slutsker; Kevin M De Cock Journal: PLoS One Date: 2009-07-31 Impact factor: 3.240
Authors: Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2016-05-31 Impact factor: 25.391
Authors: David N Burns; Victor DeGruttola; Christopher D Pilcher; Mirjam Kretzschmar; Christopher M Gordon; Elizabeth H Flanagan; Christopher Duncombe; Myron S Cohen Journal: AIDS Res Hum Retroviruses Date: 2014-02-11 Impact factor: 2.205
Authors: Bridgette M Brawner; Barbara Guthrie; Robin Stevens; Lynne Taylor; Michael Eberhart; Jean J Schensul Journal: J Urban Health Date: 2017-10 Impact factor: 3.671
Authors: Krishna P Reddy; C Robert Horsburgh; Robin Wood; Naomi F Fields; Michael P Girouard; Sydney Costantini; Taige Hou; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Mariya V Sivay; Jessica M Fogel; Jing Wang; Yinfeng Zhang; Estelle Piwowar-Manning; William Clarke; Autumn Breaud; Joel Blankson; Erica L Hamilton; Kathleen Kahn; Amanda Selin; F Xavier Gomez-Olive; Catherine MacPhail; James P Hughes; Audrey Pettifor; Susan H Eshleman Journal: HIV Clin Trials Date: 2018-12-06
Authors: Rose Wafula; Sarah Masyuko; Lucy Ng'ang'a; Andrea A Kim; Anthony Gichangi; Irene Mukui; James Batuka; Evelyn W Ngugi; William K Maina; Sandra Schwarcz Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Maya Petersen; Laura Balzer; Dalsone Kwarsiima; Norton Sang; Gabriel Chamie; James Ayieko; Jane Kabami; Asiphas Owaraganise; Teri Liegler; Florence Mwangwa; Kevin Kadede; Vivek Jain; Albert Plenty; Lillian Brown; Geoff Lavoy; Joshua Schwab; Douglas Black; Mark van der Laan; Elizabeth A Bukusi; Craig R Cohen; Tamara D Clark; Edwin Charlebois; Moses Kamya; Diane Havlir Journal: JAMA Date: 2017-06-06 Impact factor: 56.272